General Principles for the Validation of Proarrhythmia Risk Prediction Models: An Extension of the CiPA In Silico Strategy
Open Access
- 10 November 2019
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 107 (1), 102-111
- https://doi.org/10.1002/cpt.1647
Abstract
This white paper presents principles for validating proarrhythmia risk prediction models for regulatory use as discussed at the In Silico Breakout Session of a Cardiac Safety Research Consortium/Health and Environmental Sciences Institute/US Food and Drug Administration–sponsored Think Tank Meeting on May 22, 2018. The meeting was convened to evaluate the progress in the development of a new cardiac safety paradigm, the Comprehensive in Vitro Proarrhythmia Assay (CiPA). The opinions regarding these principles reflect the collective views of those who participated in the discussion of this topic both at and after the breakout session. Although primarily discussed in the context of in silico models, these principles describe the interface between experimental input and model‐based interpretation and are intended to be general enough to be applied to other types of nonclinical models for proarrhythmia assessment. This document was developed with the intention of providing a foundation for more consistency and harmonization in developing and validating different models for proarrhythmia risk prediction using the example of the CiPA paradigm.Keywords
Funding Information
- Wellcome Trust (212203/Z/18/Z)
This publication has 68 references indexed in Scilit:
- Experimentally calibrated population of models predicts and explains intersubject variability in cardiac cellular electrophysiologyProceedings of the National Academy of Sciences of the United States of America, 2013
- Quantification of repolarization reserve to understand interpatient variability in the response to proarrhythmic drugs: A computational analysisHeart Rhythm, 2011
- Simulation of the Undiseased Human Cardiac Ventricular Action Potential: Model Formulation and Experimental ValidationPLoS Computational Biology, 2011
- Simulation of multiple ion channel block provides improved early prediction of compounds’ clinical torsadogenic riskCardiovascular Research, 2011
- hERG in vitro interchange factors—development and verificationToxicology Mechanisms and Methods, 2009
- Parameter Sensitivity Analysis in Electrophysiological Models Using Multivariable RegressionBiophysical Journal, 2009
- Validation of Biomarker-Based Risk Prediction ModelsClinical Cancer Research, 2008
- A Rabbit Langendorff Heart Proarrhythmia Model: Predictive Value for Clinical Identification of Torsades de PointesBritish Journal of Pharmacology, 2006
- Prediction of the risk of Torsade de Pointes using the model of isolated canine Purkinje fibresBritish Journal of Pharmacology, 2005
- Risk-Assessment Implications of Mechanistic Model's Prediction of Low-Dose Nonlinearity of Liver Tumor Risk for Mice FED Fumonisin B1Nonlinearity in Biology, Toxicology, Medicine, 2004